CTNM: PIPE-791 advances toward 2028 completion as losses grow and PIPE-307 misses its MDD endpoint

What happened

Contineum Therapeutics reported wider third-quarter losses as spending on PIPE-791’s Phase 2 trial increased. It reported $244.5 million in cash and marketable securities, expected to support at least 12 months. PIPE-307 missed its primary trial endpoint, while PROPEL-IPF is targeted for completion in June 2028.

Confirmed

Global impact / market context

Higher PIPE-791 trial spending is increasing costs while the company reports wider losses, so research progress is not yet translating into lower expenses. The reported cash runway offers time to pursue its programs, but a missed PIPE-307 endpoint may weaken the case for that program and its future funding.

Analyst inference

The update combines a longer-dated trial milestone with near-term execution and funding risks. PROPEL-IPF’s June 2028 target means important trial completion remains ahead, while PIPE-307’s missed primary endpoint and rising PIPE-791 costs make development outcomes and cash use central to assessing the company.

Analyst inference

What to watch

1. Watch for updates on PIPE-791 Phase 2 progress and spending, because continued cost increases could use the reported cash faster than the stated runway suggests. Analyst inference
2. Look for details about PIPE-307 after its missed primary endpoint, including whether the company changes the program or reports further trial findings. Analyst inference
3. Track whether PROPEL-IPF remains targeted for June 2028 completion and whether company updates provide evidence that the timeline is still achievable. Analyst inference

Evidence

• Original source link unavailable